Date: 2015-04-17
Type of information: IPO
Company: Epizyme (USA - MA)
Investors:
Amount: $130.7 million
Funding type: IPO
Planned used: Epizyme is creating novel epigenetic therapeutics for cancer patients. Its proprietary product platform is used to create small molecule inhibitors of a 96-member class of enzymes, the histone methyltransferases. Epizyme intends to use proceeds from the offering, together with its existing cash and cash equivalents, to fund global development costs of EPZ-6438, Epizyme\'s novel EZH2 inhibitor, outside of Japan , including the costs of the planned Phase 2 portion of a Phase 1/2 clinical trial in patients with relapsed or refractory B-cell lymphoma, a planned Phase 2 trial in adult patients with INI1-deficient tumors, our planned Phase 1 trial in pediatric patients with INI1-deficient tumors, and our planned clinical pharmacology studies of EPZ-6438. The funds will also be used for two ongoing Phase 1 clinical trials of EPZ-5676, Epizyme\'s novel DOT1L inhibitor. They will also fund research and development to advance Epizyme\'s pipeline of preclinical product candidates.
Others: * On April 17, 2015, Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced that the underwriters for its underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme. The underwriters purchased 701,448 shares from Epizyme at the public offering price of $20.75 per share, less underwriting discounts. The aggregate net proceeds before expenses to Epizyme from the offering are approximately $130.7 million. * On March 18, 2015, Epizyme announced the pricing of its public offering of 6,000,000 shares of its common stock at a price of $20.75 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme . In addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price, less the underwriting discount. Leerink Partners LLC, Cowen and Company, LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager for the offering. SunTrust Robinson Humphrey, Inc. and Mizuho Securities USA Inc. are acting as co-managers for the offering. The offering is expected to close on or about March 23, 2015 , subject to customary closing conditions. A shelf registration statement relating to this offering was filed with the U.S. Securities and Exchange Commission (SEC) on June 12, 2014 , and declared effective by the SEC on June 27, 2014 . * On March 16, 2015, Epizyme announced that it intends to offer and sell up to 4,750,000 shares of its common stock in an underwritten public offering. Epizyme intends to grant the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by Epizyme . Leerink Partners LLC, Cowen and Company, LLC , and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager for the offering, and Mizuho Securities USA Inc. is acting as co-manager for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area:
